Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Université Du Mans has 1 pending office action in Biotechnology & Pharmaceuticals. The matter is assigned to 1 examiner and 1 art unit, creating a single examination context for the portfolio.
SEITZ, ANTHONY JOSEPH is the busiest examiner, with 1 pending matter. No other examiner or art-unit assignment is recorded. Counsel can concentrate prosecution planning on the examiner’s treatment of the claims and the practices of the identified unit.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SEITZ, ANTHONY JOSEPH | 1 | 68.2% | +26.9% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19021561 | DISULFONATE STILBENES FOR USE IN THE TREATMENT OF PROLIFERATIVE DISEASES | SEITZ, ANTHONY JOSEPH | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19021561 | DISULFONATE STILBENES FOR USE IN THE TREATMENT OF PROLIFERATIVE DISEASES | SEITZ, ANTHONY JOSEPH | — |
| Art Unit | Apps |
|---|---|
| 1629 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19021561 | DISULFONATE STILBENES FOR USE IN THE TREATMENT OF PROLIFERATIVE DISEASES | SEITZ, ANTHONY JOSEPH | 1629 | §102§112Other | Non-Final OA | — | Pending | Jan 15, 2025 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialUniversité Du Mans has 1 pending office actions as of November 2026, spread across 1 art units and 1 examiners.
Anthony Joseph Seitz has the most, with 1 of Université Du Mans's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.